Balakumaran K, Hugenholtz P G, Tijssen J G, Chadha D R
Eur Heart J. 1983 Sep;4(9):655-61. doi: 10.1093/oxfordjournals.eurheartj.a061538.
Molsidomine was compared with propranolol for anti-anginal efficacy in a double-blind, cross-over, fixed-dose clinical trial, involving 39 patients with moderate, stable angina pectoris, and objective evidence of coronary sclerosis. The incidence of anginal attacks under molsidomine did not differ statistically from that under propranolol. However, propranolol was more effective in reducing the nitroglycerin requirement at the doses used. Ergometry showed that both drugs increased exercise tolerance to a comparable extent. However the rate pressure product during exertion indicates that these drugs achieve this result via different paths, molsidomine having a nitrate-like effect. Unwanted effects during the four week treatment periods were minor and generally tolerable. Molsidomine is an effective long-acting anti-anginal agent with nitrate-like effects and should be a useful addition to the drugs already in use.
在一项双盲、交叉、固定剂量的临床试验中，将吗多明与普萘洛尔的抗心绞痛疗效进行了比较。该试验纳入了39例中度、稳定型心绞痛且有冠状动脉硬化客观证据的患者。吗多明治疗期间心绞痛发作的发生率与普萘洛尔治疗期间相比，在统计学上无差异。然而，在所使用的剂量下，普萘洛尔在降低硝酸甘油需求量方面更有效。运动试验表明，两种药物在提高运动耐量方面程度相当。然而，运动期间的速率压力乘积表明，这些药物通过不同途径达到这一结果，吗多明具有类似硝酸盐的作用。四周治疗期内的不良反应轻微，通常可以耐受。吗多明是一种有效的长效抗心绞痛药物，具有类似硝酸盐的作用，应该是现有药物的有益补充。
